HAMILTON, Bermuda, September 21, 2006 – PRNewswire-FirstCall — Warner Chilcott Limited today announced the pricing of its initial public offering of 70,600,000 shares of common stock, at a price of $15 per share. The shares will be listed on the Nasdaq Global Select Market and will trade under the symbol “WCRX” beginning September 21, 2006. The 70,600,000 shares will be sold by the Company.
The underwriters have an option to purchase up to an additional 7,060,000 shares from the selling stockholders at the initial public offering price less the underwriting discount. The Company will not receive any proceeds from a sale of the shares by the selling stockholders if the underwriters exercise their option to purchase additional shares.
Goldman, Sachs & Co., Credit Suisse Securities (USA) LLC, J.P. Morgan Securities Inc. and Morgan Stanley have acted as joint book-running managers for the offering.
A copy of the final prospectus relating to these securities may be obtained, when available, from: Goldman, Sachs & Co., Attn: Prospectus Department, 85 Broad Street, New York, NY 10004 via fax at (212) 902-9316 or email at email@example.com.
This release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any State in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such State.
Warner Chilcott is a leading specialty pharmaceutical company focused on marketing, selling, developing and manufacturing branded prescription products in women’s healthcare and dermatology in the United States.
SOURCE Warner Chilcott
Contact for Avista Capital Partners:
Diana Postemsky, Kekst and Company, 212-521-4805